» Articles » PMID: 2964497

Role of T Cell Subsets in Lethal Graft-versus-host Disease (GVHD) Directed to Class I Versus Class II H-2 Differences. I. L3T4+ Cells Can Either Augment or Retard GVHD Elicited by Lyt-2+ Cells in Class I Different Hosts

Overview
Journal J Exp Med
Date 1988 Feb 1
PMID 2964497
Citations 21
Authors
Affiliations
Soon will be listed here.
Abstract

Detailed information was sought on the capacity of purified Lyt-2+ cells to mediate lethal graft-versus-host disease (GVHD) directed to class I H-2 differences. When B6 Lyt-2+ cells were transferred to irradiated class I-different (B6 x bm 1)F1 mice, three different patterns of lethal GVHD were observed. First, rapid death from hematopoietic failure occurred when Lyt-2+ cells were transferred together with host-type marrow cells; this form of GVHD probably reflected direct destruction of stem cells by Lyt-2+ cytotoxic cells. Second, a pattern of late-onset, chronic GVHD resulting in death only after 4-6 wk occurred when Lyt-2+ cells were supplemented with donor marrow. This syndrome developed in the apparent absence of L3T4+ cells and was observed with either high or low doses of Lyt-2+ cells and with either light or heavy irradiation of the host. Third, an acute form of GVHD resulted when Lyt-2+ cells plus donor marrow cells were supplemented with exogenous help, i.e., by adding small doses of donor L3T4+ cells or injecting the hosts with rIL-2. Although L3T4+ cells potentiated GVHD when injected in small doses, supplementing Lyt-2+ cells with large doses of L3T4+ cells paradoxically led to marked protection; symptoms of GVHD were mild and no deaths occurred.

Citing Articles

Protocol for X-ray irradiation of C57BL/6J recipient mice followed by the transplantation of mTomato-expressing bone marrow cells.

Vo T, Kumar R, Lamichhane R, Choudhary I, Kc R, Mao Y STAR Protoc. 2024; 6(1):103504.

PMID: 39700013 PMC: 11728988. DOI: 10.1016/j.xpro.2024.103504.


Insights into mechanisms of graft-versus-host disease through humanised mouse models.

Elhage A, Sligar C, Cuthbertson P, Watson D, Sluyter R Biosci Rep. 2022; 42(9).

PMID: 35993192 PMC: 9446388. DOI: 10.1042/BSR20211986.


Purinergic Signalling in Allogeneic Haematopoietic Stem Cell Transplantation and Graft-versus-Host Disease.

Cuthbertson P, Geraghty N, Adhikary S, Bird K, Fuller S, Watson D Int J Mol Sci. 2021; 22(15).

PMID: 34361109 PMC: 8348324. DOI: 10.3390/ijms22158343.


Mouse nidovirus LDV infection alleviates graft versus host disease and induces type I IFN-dependent inhibition of dendritic cells and allo-responsive T cells.

Gaignage M, Marillier R, Uyttenhove C, Dauguet N, Saxena A, Ryffel B Immun Inflamm Dis. 2017; 5(2):200-213.

PMID: 28474504 PMC: 5418140. DOI: 10.1002/iid3.157.


Pathophysiology of GvHD and Other HSCT-Related Major Complications.

Ghimire S, Weber D, Mavin E, Wang X, Dickinson A, Holler E Front Immunol. 2017; 8:79.

PMID: 28373870 PMC: 5357769. DOI: 10.3389/fimmu.2017.00079.


References
1.
Gale R, Reisner Y . Graft rejection and graft-versus-host disease: mirror images. Lancet. 1986; 1(8496):1468-70. DOI: 10.1016/s0140-6736(86)91503-5. View

2.
Goronzy J, Weyand C, Fathman C . Long-term humoral unresponsiveness in vivo, induced by treatment with monoclonal antibody against L3T4. J Exp Med. 1986; 164(3):911-25. PMC: 2188395. DOI: 10.1084/jem.164.3.911. View

3.
Cobbold S, Martin G, Waldmann H . Monoclonal antibodies for the prevention of graft-versus-host disease and marrow graft rejection. The depletion of T cell subsets in vitro and in vivo. Transplantation. 1986; 42(3):239-47. DOI: 10.1097/00007890-198609000-00003. View

4.
Mizuochi T, Munitz T, McCarthy S, Andrysiak P, Kung J, Gress R . Differential helper and effector responses of Lyt-2+ T cells to H-2Kb mutant (Kbm) determinants and the appearance of thymic influence on anti-Kbm CTL responsiveness. J Immunol. 1986; 137(9):2740-7. View

5.
Malkovsky M, Brenner M, Hunt R, Rastan S, Dore C, Brown S . T-cell depletion of allogeneic bone marrow prevents acceleration of graft-versus-host disease induced by exogenous interleukin 2. Cell Immunol. 1986; 103(2):476-80. DOI: 10.1016/0008-8749(86)90108-5. View